Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 9/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 5/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290311 | 1.00 | ITGAL (0.58) | ITGALAPPITGB2ICAM1PTGS2 | |
| SCHEMBL4283957 | 0.85 | ITGAL (0.67) | ITGALITGB2ICAM1NPC1BCHE | |
| SCHEMBL4283960 | 0.85 | ITGAL (0.67) | ITGALITGB2ICAM1NPC1BCHE | |
| SCHEMBL4771364 | 0.84 | ITGAL (0.63) | ITGALITGB2ICAM1NPC1AR | |
| SCHEMBL13879663 | 0.83 | ITGAL (0.58) | ITGALITGB2ICAM1PTGS2L3MBTL1 | |
| SCHEMBL4277188 | 0.80 | NPC1 (0.41) | ITGALITGB2ICAM1NPC1L3MBTL1 | |
| SCHEMBL4277195 | 0.80 | NPC1 (0.41) | ITGALITGB2ICAM1NPC1L3MBTL1 | |
| SCHEMBL13879651 | 0.80 | ITGAL (0.57) | ITGALITGB2ICAM1NPC1L3MBTL1 | |
| SCHEMBL4276624 | 0.78 | ITGAL (0.57) | ITGALITGB2ICAM1NPC1L3MBTL1 | |
| SCHEMBL4276627 | 0.78 | ITGAL (0.57) | ITGALITGB2ICAM1NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ITGAL 4495/4885APP 4226/4885ITGB2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.